Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus NAFAZAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus NAFAZAIR.
KENALOG IN ORABASE vs NAFAZAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Unknown. It is a purified fatty acid derivative that may modulate inflammatory responses.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
2.5 mg subcutaneously once daily.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
Terminal elimination half-life is 6-8 hours; in moderate renal impairment (CrCl 30-50 mL/min) extends to 12-15 hours.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Primarily renal excretion (70-80% as unchanged drug), with 15-20% fecal elimination via biliary secretion.
Category C
Category C
Corticosteroid
Intranasal Antihistamine/Corticosteroid